Key result
Paclitaxel DCBs for dysfunctional dialysis circuits yield a ~13% 12-month serious infection rate.
Why the study?
Safety and effectiveness data of paclitaxel drug-coated balloons for treating de novo or restenotic lesions in native arteriovenous fistulae in hemodialysis patients were needed.
Does paclitaxel drug-coated balloon treatment maintain patency and prevent serious infections in hemodialysis patients with dysfunctional arteriovenous fistulae?
Does paclitaxel drug-coated balloon treatment maintain patency and prevent serious infections in hemodialysis patients with dysfunctional arteriovenous fistulae?
Paclitaxel drug-coated balloons demonstrated safety and durability for treating de novo and restenotic arteriovenous fistula lesions in hemodialysis patients, with a low 12-month serious infection rate.
Supports DCB safety in hemodialysis AVF; leaves open randomized confirmation of patency benefits.
No takes yet. Share an insight, caveat, or question.
Misra et al. (2026) studied Dysfunctional arteriovenous dialysis circuits (n=159). Paclitaxel drug-coated balloon vs. 30% performance goal was evaluated on Serious infection rate through 12 months, including pneumonia but excluding coronavirus disease 2019 (95% CI 8.9-20.1). Treatment of dysfunctional arteriovenous dialysis circuits with a paclitaxel drug-coated balloon resulted in a 12-month serious infection rate of 13.4% (95% CI, 8.9-20.1%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: